Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Idera Pharmaceuticals has received new patents covering its novel immune modulatory oligonucleotides, or IMO, chemical modifications of IMOs, compositions containing IMOs with other therapeutic agents, and the use of IMOs to therapeutically treat a range of diseases.
Subscribe to our email newsletter
Steven Ritter, vice president of intellectual property and contracts at Idera, said: “We continue to strengthen Idera’s patent portfolio covering compounds targeted to Toll-like receptors. The claims of these issued patents cover the therapeutic use of our immune stimulatory oligonucleotide compounds and specific compositions that may be useful in selected disease areas.
“This patent protection is a fundamental component of our strategy of using a chemistry-based approach to discover and develop TLR-targeted compounds for the treatment of a variety of diseases.”
Presently, the company said that it holds over 260 issued patents and pending patent applications worldwide, which cover novel agonists and antagonists of TLR7, 8 and 9.